Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease

NCT05612035 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT05612035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05612035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 16, 2023
Completion date
October 8, 2029
Enrollment
129 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease, pulmonary hypertension